Resultados: 2

Cost comparison of dupilumab and omalizumab for the treatment of severe allergic asthma patients from the Brazilian private healthcare system perspective

Magro, Frederico José Bighetti; Barbosa, Aline; Taminato, Alexandre; Migliavaca, Celina Borges; Federico, Priscila; Tebyriçá, Renata Nahuys; Cançado, Jose Eduardo D; Giavina-Bianchi, Pedro; Falavigna, Maicon.

J. bras. econ. saúde (Impr.); 14 (3), 2022

Objective: To compare the costs of dupilumab and omalizumab for treating severe allergic asthma patients from the perspective of the Brazilian private healthcare system. Methods: Using clinical and demographic inputs from the literature, we simulated a cohort of 5,000 severe allergic asthma patients and ...

Asma, Custos e Análise de Custo, Omalizumab

Texto completo

Cost of chronic red blood cell transfusion in the Brazilian private healthcare sector from a payer perspective

Magro, Frederico José Bighetti; Ribeiro, Rodrigo Antonini; Sekine, Leo; Marinato, André Fiorin; Samir, Kanaan Nabhan; Stefani, Stephen Doral; Marques Junior, José Francisco Comenalli.

J. bras. econ. saúde (Impr.); 12 (3), 2020

Objective: In the private healthcare sector in Brazil, the dearth of information regarding transfusion cost may compromise the management of conditions requiring long-term transfusion. Therefore, the present study aimed to estimate the cost of chronic red blood cell (RBC) transfusion in this context. Met...

Transfusão de Sangue, Eritrócitos, Saúde Suplementar

Texto completo (link principal) Texto completo (link alternativo)